We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

EVIO to Purchase Licensed Cannabis Laboratory in Northern California

EVIO has announced that it has signed a non-binding letter of intent to acquire 60% of C3 Labs.

Read More

Shimadzu Scientific Instruments and Restek Corporation Announce Distribution Agreement

Shimadzu Scientific Instruments (SSI) and Restek Corporation have entered a partnership that enables the sales of Restek consumables by SSI.

Read More

New Player Enters Californian Cannabis Testing Market

Formed by Sachin Barot and Denis Chen, the CERESLabs mission is to become the global leader in analytical cannabis product testing.

Read More

Steep Hill, Eybna Partner to Commercialize Customized Cannabis Terpene Products

The partnership will utilize Steep Hill's expertise in analytical testing to customize Eybna's production of terpene formulations for optimizing the medical benefits of cannabis.

Read More

Taking Advantage of Canada’s Cannabis Testing Market

Third party lab testing isn’t currently required by Health Canada, but the agency has already required ‘expanded’ testing for licensed producers to ensure that pesticide and additive requirements are being met.

Read More

Steep Hill Expands Into Oregon

Jmîchaeĺe Keller, President and CEO of Steep Hill has announced that it has licensed its cannabis testing technology to highly respected pain and addiction physician Dr. Carl Balog.

Read More

Cannabis Medicine: Providing Patients with the Right Chemical Profile for Their Condition

Analyzing the complex chemistry of the cannabis plant may help scientists to develop specific cannabis-based drugs for specific conditions.

Read More

Only So Green: Pesticides in Cannabis Clones

Pesticides in the environment alone could push cannabis above some regulatory limits.

Read More

Almost 70% of CBD Extracts Sold Online Are Mislabeled

Products containing either too little or too much CBD than labeled could negate potential clinical benefit to patients.

Read More

 
Advertisement